© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Centering discussion on a patient case of endometrial cancer, expert oncologist Bhavana Pothuri, MD, highlights systemic therapy and best practices in this setting.
September 26th 2022
Expert oncologist Bhavana Pothuri, MD, reviews the diagnosis and treatment of a 64-year-old woman who presents and recurs with mismatch repair-deficient (dMMR) endometrial cancer (EC).
Expert perspective on the presentation of endometrial cancer, followed by advice on providing optimal workup and diagnosis.
Comprehensive insight to the systemic treatment armamentarium available to patients with metastatic EC.
Centering discussion on safety and efficacy data from the GARNET trial, Bhavana Pothuri, MD, reflects on the role of dostarlimab therapy in patients with recurrent metastatic endometrial cancer.
Focusing on patients with recurrent metastatic endometrial cancer, an expert oncologist identifies factors that help inform the selection of second-line targeted therapy.
Bhavana Pothuri, MD provides a perspective on the management of immune-related adverse events that can be seen in patients treated for recurrent metastatic endometrial cancer, as well as a focused discussion on the conversations she has with her patients.
Closing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.